These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

893 related items for PubMed ID: 27039770

  • 1. Ki67 Frequency in Breast Cancers without Axillary Lymph Node Involvement and its Relation with Disease-free Survival.
    Shandiz FH, Shabahang H, Afzaljavan F, Sharifi N, Tavasoli A, Afzalaghaee M, Roshanzamir E, Pasdar A.
    Asian Pac J Cancer Prev; 2016; 17(3):1347-50. PubMed ID: 27039770
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
    Yan J, Liu XL, Han LZ, Xiao G, Li NL, Deng YN, Yin LC, Ling LJ, Yu XY, Tan CL, Huang XP, Liu LX.
    Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
    [Abstract] [Full Text] [Related]

  • 4. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
    Ono M, Tsuda H, Yoshida M, Shimizu C, Kinoshita T, Tamura K.
    Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
    [Abstract] [Full Text] [Related]

  • 5. Ki67 expression in breast cancer. Correlation with prognostic markers and clinicopathological parameters in Saudi patients.
    Elkablawy MA, Albasri AM, Mohammed RA, Hussainy AS, Nouh MM, Alhujaily AS.
    Saudi Med J; 2016 Feb; 37(2):137-41. PubMed ID: 26837394
    [Abstract] [Full Text] [Related]

  • 6. Ki-67 is a prognostic marker for hormone receptor positive tumors.
    Pérez-López ME, García-Gómez J, Alves MT, Paradela A, García-Mata J, García-Caballero T.
    Clin Transl Oncol; 2016 Oct; 18(10):996-1002. PubMed ID: 26742937
    [Abstract] [Full Text] [Related]

  • 7. Prognostic significance of geminin expression levels in Ki67-high subset of estrogen receptor-positive and HER2-negative breast cancers.
    Yagi T, Inoue N, Yanai A, Murase K, Imamura M, Miyagawa Y, Enomoto Y, Nishimukai A, Takatsuka Y, Hirota S, Akazawa K, Miyoshi Y.
    Breast Cancer; 2016 Mar; 23(2):224-30. PubMed ID: 25082658
    [Abstract] [Full Text] [Related]

  • 8. Clinicopathological and prognostic characteristics of triple- negative breast cancer (TNBC) in Chinese patients: a retrospective study.
    Li CY, Zhang S, Zhang XB, Wang P, Hou GF, Zhang J.
    Asian Pac J Cancer Prev; 2013 Mar; 14(6):3779-84. PubMed ID: 23886182
    [Abstract] [Full Text] [Related]

  • 9. Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.
    Ibrahim T, Farolfi A, Scarpi E, Mercatali L, Medri L, Ricci M, Nanni O, Serra L, Amadori D.
    Oncology; 2013 Mar; 84(3):150-7. PubMed ID: 23257904
    [Abstract] [Full Text] [Related]

  • 10. Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
    Buta M, Džodić R, Đurišić I, Marković I, Vujasinović T, Markićević M, Nikolić-Vukosavljević D.
    Tumour Biol; 2015 Sep; 36(10):8193-200. PubMed ID: 25994573
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Axillary lymph node recurrence after sentinel lymph node biopsy performed using a combination of indocyanine green fluorescence and the blue dye method in early breast cancer.
    Inoue T, Nishi T, Nakano Y, Nishimae A, Sawai Y, Yamasaki M, Inaji H.
    Breast Cancer; 2016 Mar; 23(2):295-300. PubMed ID: 25348937
    [Abstract] [Full Text] [Related]

  • 13. Ki67 index in breast cancer: correlation with other prognostic markers and potential in pakistani patients.
    Haroon S, Hashmi AA, Khurshid A, Kanpurwala MA, Mujtuba S, Malik B, Faridi N.
    Asian Pac J Cancer Prev; 2013 Mar; 14(7):4353-8. PubMed ID: 23992002
    [Abstract] [Full Text] [Related]

  • 14. Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients.
    Laurberg T, Alsner J, Tramm T, Jensen V, Lyngholm CD, Christiansen PM, Overgaard J.
    Acta Oncol; 2017 Jan; 56(1):59-67. PubMed ID: 27846764
    [Abstract] [Full Text] [Related]

  • 15. Back to Basics: Traditional Nottingham Grade Mitotic Counts Alone are Significant in Predicting Survival in Invasive Breast Carcinoma.
    Chang JM, McCullough AE, Dueck AC, Kosiorek HE, Ocal IT, Lidner TK, Gray RJ, Wasif N, Northfelt DW, Anderson KS, Pockaj BA.
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S509-15. PubMed ID: 26001860
    [Abstract] [Full Text] [Related]

  • 16. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer.
    Min KW, Kim DH, Do SI, Pyo JS, Chae SW, Sohn JH, Kim K, Lee HJ, Kim DH, Oh S, Choi SH, Park YL, Park CH, Kwon MJ, Moon KM.
    Postgrad Med J; 2016 Dec; 92(1094):707-714. PubMed ID: 27222586
    [Abstract] [Full Text] [Related]

  • 17. Prognostic significance of Ki-67 in chemotherapy-naive breast cancer patients with 10-year follow-up.
    Nishimiya H, Kosaka Y, Yamashita K, Minatani N, Kikuchi M, Ema A, Nakamura K, Waraya M, Sengoku N, Tanino H, Kuranami M, Watanabe M.
    Anticancer Res; 2014 Jan; 34(1):259-68. PubMed ID: 24403472
    [Abstract] [Full Text] [Related]

  • 18. Retrospective analysis of risk factors for central nervous system metastases in operable breast cancer: effects of biologic subtype and Ki67 overexpression on survival.
    Ishihara M, Mukai H, Nagai S, Onozawa M, Nihei K, Shimada T, Wada N.
    Oncology; 2013 Jan; 84(3):135-40. PubMed ID: 23235554
    [Abstract] [Full Text] [Related]

  • 19. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
    Li Y, Zhang X, Qiu J, Pang T, Huang L, Zeng Q.
    J BUON; 2019 Jan; 24(6):2361-2368. PubMed ID: 31983107
    [Abstract] [Full Text] [Related]

  • 20. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
    Eggemann H, Ignatov T, Burger E, Kantelhardt EJ, Fettke F, Thomssen C, Costa SD, Ignatov A.
    Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.